GP681
Phase 3Small molecule
GP681 is one of 36 small molecule programs targeting Complication. It is currently in Phase 3.
2
Indications
10
Total Trials
2
Active Trials
35
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
95 competitors in Influenza
#DrugCompanyPhaseTrials
1Influenza Vaccine
NovartisPhase 3
FLU Vaccine
GSKPhase 3
Inactivated Influenza Vaccine
SanofiPhase 3
Seasonal Influenza Vaccine
NovartisPhase 3
Live Attenuated Zoster Vaccine
CChangchun BCHT Biotechnology Co.
Phase 3
COVID-19 Vaccine
ModernaPhase 2
Relenza
GGlaxo Dba Glaxosmithkline
Phase 3
VAXIGRIP
GSKPhase 3
Dexametasone
UUniversity of Malaya
Phase 3
GP681
JJiangxi Qingfeng Pharmaceutical Co. Ltd.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Influenza3 trials
Hepatic Impairment1 trial
Drug Interactions1 trial
Complication1 trial
3 more indications
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for GP681. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details